{"id":"W4403176298","doi":"10.1016/s1473-3099(24)00499-7","title":"Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"Nosocomial Infections in ICU","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"Innovative Medicines Initiative; Innovative Health Initiative; Pfizer","keywords":"Aztreonam; Descriptive statistics; Gram-negative bacteria; Ceftazidime/avibactam; Open label; Medicine; Gram; Meropenem; Internal medicine; Randomized controlled trial; Microbiology; Bacteria; Biology; Statistics; Antibiotics; Mathematics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003416884,0.0004071946,0.0008951203,0.0001431568,0.0006981045,0.0002991378,0.0002945524,0.0001001254,0.0003109984],"category_scores_gemma":[0.0009623611,0.000236456,0.0003712371,0.0006303391,0.0003794496,0.0002928751,0.00007796109,0.0002012655,0.00003439767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006000269,"about_ca_system_score_gemma":0.000401567,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005084765,"about_ca_topic_score_gemma":0.0002069931,"domain_scores_codex":[0.9979582,0.0003406446,0.0005633071,0.0004660181,0.0002711648,0.0004006669],"domain_scores_gemma":[0.9942433,0.004354121,0.0002448493,0.000679731,0.0003239265,0.0001541306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6059921,0.04241981,0.001195803,0.0006635024,0.01592307,0.00004876307,0.003454995,0.0002191699,0.02820427,0.0038619,0.169912,0.1281046],"study_design_scores_gemma":[0.7914743,0.01811352,0.0007127596,0.0002385992,0.005470995,0.000028196,0.0002126778,0.0009391065,0.008720192,0.0007332153,0.1728904,0.000466123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967827,0.004061371,0.001264055,0.001888282,0.004048218,0.01662215,0.002228762,0.0005770124,0.00148313],"genre_scores_gemma":[0.985137,0.003968886,0.0001173617,0.0002453442,0.00162299,0.007793079,0.0003788449,0.0000946551,0.0006417971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1854821,"threshold_uncertainty_score":0.9642397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08018690272348557,"score_gpt":0.3962698453132819,"score_spread":0.3160829425897963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}